LRRK2 inhibitor 1 is primarily used in research focused on understanding and treating Parkinson's disease. It specifically targets the LRRK2 kinase enzyme, which is implicated in the pathogenesis of the disease. By inhibiting this enzyme, it helps in studying the underlying mechanisms of neurodegeneration and potential therapeutic strategies. Additionally, it is utilized in preclinical studies to evaluate its efficacy and safety as a potential drug candidate for Parkinson's and other related disorders.